# Biorchestra Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biorchestra-co

- Industry: Biotechnology
- Headquarters: Daejeon, South Korea
- Website: www.biorchestra.com
- Total disclosed funding: $64M
- Latest round: Series C (Feb 22, 2022)
- Investors on record: 15

## About

Founded in 2016 by CEO Branden Ryu, and based in Seoul, South Korea, Biorchestra Co., Ltd. operates as a biotech company that works on the research and development of ribonucleic acid (RNA) based therapeutics. In February 2022, Biorchestra Co., Ltd. raised KRW 54.5 billion in Series C funding from Chong Kun Dang Holdings Corp., Chong Kun Dang Pharm., GS Holdings, DAYLI Partners, E&Venture Partners, IMM Investment, LSK Investment, and some other investors. 

The company develops a treatment for RNA-based degenerative brain diseases such as Alzheimer’s and Lou Gehrig’s disease. The company also provides other services including drug delivery system, RNA therapeutics, diagnostics, and clinical approaches. 

The company plans to use the Series C funding for its clinical trials and sample production of its new drug, to increase new pipelines with the US subsidiary, prepare for drug delivery system factory production, and for its joint research with domestic and foreign pharmaceutical companies.

## Funding rounds

- Series C, Feb 22, 2022, $45M — STIC Investments, SBI Investment Korea, Smilegate Investment, IMM Investment, NH Investment & Securities, LSK Investment, Quantum Ventures Korea, Widwin Investment, Chong Kun Dang Pharm., E&Venture Partners, DAYLI Partners, GS Holdings, Chong Kun Dang Holdings Corp.
- Series B, Aug 14, 2019, $16M — SBI Investment Korea, CKD Venture Capital, NHN Investment, LSK Investment, E&Venture Partners, DAYLI Partners, Chong Kun Dang Holdings Corp.
- Series A, Sep 28, 2018, $3M — DAYLI Partners

## Investors

- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series A, Series B, Series C
- SBI Investment Korea (https://capitalatlas.ai/funds/sbi-investment-korea) — Series B, Series C
- CKD Venture Capital (https://capitalatlas.ai/funds/ckd-venture-capital) — Series B
- NHN Investment (https://capitalatlas.ai/funds/nhn-investment) — Series B
- LSK Investment (https://capitalatlas.ai/funds/lsk-investment) — Series B, Series C
- E&Venture Partners (https://capitalatlas.ai/funds/e-venture-partners) — Series B, Series C
- Chong Kun Dang Holdings Corp. — Series B, Series C
- STIC Investments (https://capitalatlas.ai/funds/stic-investments) — Series C
- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series C
- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series C
- NH Investment & Securities (https://capitalatlas.ai/funds/nh-investment-securities) — Series C
- Quantum Ventures Korea (https://capitalatlas.ai/funds/quantum-ventures-korea) — Series C
- Widwin Investment (https://capitalatlas.ai/funds/widwin-investment) — Series C
- Chong Kun Dang Pharm. — Series C
- GS Holdings — Series C